Helpful resources

1. Verstovsek S, Pemmaraju N, Reaven NL, et al. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol. 2023;102(3):571-581. doi:10.1007/s00277-023-05089-6. 2. Verstovsek S, Pemmaraju N, Reaven NL, et al. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Electronic Supplemental Material. Ann Hematol. 2023;102(3):571-581. doi:10.1007/s00277-023-05089-6. 3. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33. doi:10.1056/NEJMoa1208500. 4. Poullet A, Busque L, Sirhan S, et al. Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN research group. Blood Cancer J. 2025;15(1):51. doi:10.1038/s41408-025-01234-8. 5. Randrianarisoa RMF, Ramanandafy H, Mania A, et al. Prevalence and diagnostic performance of iron deficiency in polycythemia. Hematology. 2023;28(1):2204621. doi:10.1080/16078454.2023.2204621. 6. Kuykendall AT, Fine JT, Kremyanskaya M. Contemporary challenges in polycythemia vera management from the perspective of patients and physicians. Clin Lymphoma Myeloma Leuk. 2024;24(8):512-522. doi: 10.1016/j.clml.2024.04.003. 7. Ginzburg YZ, Feola M, Zimran E, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105-2116. doi:10.1038/s41375-018-0207-9. 8. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667-679. doi:10.1182/blood-2016-10-695940. 9. Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595-600. doi: 10.3109/10428194.2013.813500. 10. Grunwald MR, Burke JM, Kuter DJ, et al. Symptom burden and blood counts in patients with polycythemia vera in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk. 2019;19(9):579-584.e1. doi:10.1016/j.clml.2019.06.001. 11. Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(9):1465-1487. doi:10.1002/ajh.27002. 12. Zhao ZJ, Vainchenker W, Krantz SB et al. Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol. 2005;42(4):221-229. doi: 10.1053/j.seminhematol.2005.05.019. 13. Ling B, Xu Y, Qian S, Xiang Z, Xuan S, Wu J. Regulation of hematopoietic stem cells differentiation, self-renewal, and quiescence through the mTOR signaling pathway. Front Cell Dev Biol. 2023;11:1186850. doi:10.3389/fcell.2023.1186850. 14. Waggoner M. Polycythemia Vera: Thinking Beyond the Hematocrit. J Adv Pract Oncol. 2023;14(5):405-413. doi: 10.6004/jadpro.2023.14.5.5. 15. Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98(5):1071-1082. doi:10.1007/s00277-019-03625-x. 16. MPN Research Foundation. Polycythemia Vera (PV). Updated 2025. Accessed August, 2025. Available at: https://www.mpnresearchfoundation.org/mpn-research/polycythemia-vera. 17. Leukemia & Lymphoma Society. Polycythemia Vera Facts. Revised April, 2015. Accessed August, 2025. Available at: https://www.lls.org. 18. Leukemia & Lymphoma Society. Myeloproliferative Neoplasms: In Detail. https://www.lls.org. Revised 2025. Accessed August 25, 2025. 19. National Organization for Rare Disorders (NORD). Polycythemia vera. National Organization for Rare Disorders (NORD). Revised November 2023. Accessed August, 2025. https://rarediseases.org/rare-diseases/polycythemia-vera/. 20. Cuthbert D, Stein BL. Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes. J Blood Med. 2019;10:359-371. doi:10.2147/JBM.S189922. 21. Brabrand M, Frederiksen H. Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications. Cancers. 2020;12(10):3061. doi:10.3390/cancers12103061. 22. Pemmaraju N, Markova A, Masarova L, et al. Prevalence of second cancers in patients with polycythemia vera (PV): a retrospective analysis of US real-world claims data. Poster presented at: The 65th ASH Annual Meeting. The 65th ASH Annual Meeting; November 2, 2023; San Diego, CA. 23. Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167. doi:10.1186/s12885-016-2208-2. 24. Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey. Cancer. 2017;123(3):449-458. doi:10.1002/cncr.30325. 25. National Cancer Institute. Coping With Cancer: Feelings and Cancer. Updated April, 2025. Accessed August, 2025. Available at: https://www.cancer.gov/about-cancer/coping/feelings. 26. Bradford A, Young K, Whitechurch A, et al. Disabled, invisible and dismissed-The lived experience of fatigue in people with myeloproliferative neoplasms. Cancer Rep (Hoboken). 2023;6(1):e1655. doi:10.1002/cnr2.1655. 27. Verstovsek S, Harrison CN, Kiladjian JJ, et al. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res. 2017;56:52-59. doi:10.1016/j.leukres.2017.01.032. 28. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199-1203. doi:10.1016/j.leukres.2009.01.035. 29. Cleveland Clinic. Polycythemia Vera. Revised April, 2022. Accessed August, 2025. Available at: https://my.clevelandclinic.org/health/diseases/9223-polycythemia-vera. 30. Song J, Kim SJ, Min G, et al. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and translational. Iron Deficiency Correction in Myeloproliferative Neoplasms Reduces Thrombosis Risk Via Decreased Pelectin.  Poster presented at: The 66th ASH Annual Meeting; December 7, 2024; San Diego, CA. 31. Hung SH, Lin HC, Chung SD. Association between venous thromboembolism and iron-deficiency anemia: a population-based study. Blood Coagul Fibrinolysis. 2015;26(4):368-372. doi:10.1097/MBC.0000000000000249. 32. Barbui T. Appropriate management of Polycythemia Vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Hematol Transfus Cell Ther. 2022;44(1):S3-S4. doi:10.1016/j.htct.2022.09.1190. 33. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. N Engl J Med. 2004;350(2):114-124. doi: 10.1056/NEJMoa035572. 34. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35(12):3339-3351. doi: 10.1038/s41375-021-01401-3. 35. Visweshwar N, Fletcher B, Jaglal M, et al. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera. J Clin Med. 2024;13(16):4952. doi: 10.3390/jcm13164952. 36. Silver RT, Abu-Zeinah G. Polycythemia vera: aspects of its current diagnosis and initial treatment. Expert Rev Hematol. 2023;16(4):253-266. doi: 10.1080/17474086.2023.2198698. 37. Kim KH, Oh KY. Clinical applications of therapeutic phlebotomy. J Blood Med. 2016;7:139-144. doi:10.2147/JBM.S108479. 38. Boccia RV, Sanz-Altamira PM, Khan KD, et al. Examining the frequency of phlebotomy in patients with polycythemia vera (PV) in the United States: An analysis of data from the REVEAL Study. Blood. 2017;130(1):5271. doi:10.1182/blood.V130.Suppl_1.5271.5271. 39. Edahiro Y, Komatsu N. Iron deficiency and phlebotomy in patients with polycythemia vera. Int J Hematol. 2025;121(1):39-44. doi: 10.1007/s12185-024-03868-z. 40. Bennett C, Jackson VE, Pettikiriarachchi A, et al. Iron homeostasis governs erythroid phenotype in polycythemia vera. Blood. 2023;141(26):3199-3214. doi: 10.1182/blood.2022016779. 41. Assi TB, Baz E. Current applications of therapeutic phlebotomy. Blood Transfus. 2014;12 (Suppl 1):s75-83. doi:10.2450/2013.0299-12. 42. Mayo Clinic. Hydroxyurea (oral route). Updated August, 2025. Accessed August, 2025. Available at: https://www.mayoclinic.org/drugs-supplements/hydroxyurea-oral-route/description/drg-20068109. 43. Parasuraman S, DiBonaventura M, Reith K, et al. Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol. 2016;5:3. doi:10.1186/s40164-016-0031-8. 44. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363-1369. doi:10.1182/blood-2011-10-387787. 45. Jakafi (ruxolitinib). Package insert. Incyte Corporation; 2023. 46. BESREMi (ropeginterferon alfa-2b-njft). Package insert. PharmaEssentiaⓇ USA Corporation; 2024. 47. Vachhani P, Mascarenhas J, Bose P, et al. Interferons in the treatment of myeloproliferative neoplasms. Ther Adv Hematol. 2024;15:1-22. doi:10.1177/20406207241229588. 48. Tremblay D, Ronner L, Podoltsev N, et al. J. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res. 2021;109:106629. doi:10.1016/j.leukres.2021.106629. 49. Chamseddine RS, Savenkov O, Rana S. Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes. Blood Adv. 2024;8(10):2520-2526. doi:10.1182/bloodadvances.2023012459. 50. Abelsson J, Andréasson B, Samuelsson et al. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma. 2013;54(10):2226-2230. doi:10.3109/10428194.2013.766732. 51. American Cancer Society. Adjusting to Life with Cancer. Updated January, 2019. Accessed August, 2025. Available at: https://www.cancer.org/cancer/survivorship/coping/adjusting-to-life-with-cancer.html. 52. Ponce RKM, Verma K, Gergen-Barnett K, et al. A review of medical mistrust across the cancer continuum of care and current interventions. J Community Health. 2025;50(4):750-760. doi:10.1007/s10900-025-01462-w. 53. Handa S, Ginzburg Y, Hoffman R, et al. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. Curr Opin Hematol. 2023;30(2):45-52. doi:10.1097/MOH.0000000000000747. 54. McFarland DC, Shaffer KM, Polizzi H, et al. Associations of physical and psychologic symptom burden in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Psychosomatics. 2018;59(5):472-480. doi:10.1016/j.psym.2018.01.006. 55. Poullet A, Busque L, Sirhan S, et al. Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN Research Group. Blood Cancer J. 2025;15:51. doi:10.1038/s41408-025-01234-8. Supplemental Figure 1. 56. Yu J, Parasuraman S, Paranagama D, et al. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey. BMC Cancer. 2018;18:420. doi:10.1186/s12885-018-4322-9. 57. National Institutes of Health (NIH). Talking to Your Doctor. Updated December, 2016. Accessed August, 2025. Available at: https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/clear-communication/talking-your-doctor. 58. Harrison CN, Ross DM, Fogliatto LM, et al. Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey. Hemasphere. 2025;9(3):e70106. doi:10.1002/hem3.70106. 59. Manz K, Heidel FH, Koschmieder S,et al. Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment—an intraindividual analysis by the German Study Group for MPN (GSG-MPN). Leukemia. 2025;39(4):864-875. doi:10.1038/s41375-025-02524-7. 60. Emanuel RM, Dueck AC, Geyer HL. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098-103. doi:10.1200/JCO.2012.42.3863. 61. Song J, Kim SJ, Thiagarajan P, et al. Iron Deficiency in Polycythemia Vera Increases HIF Activity and Transcription of Prothrombotic Genes. Poster presented at: The 63rd ASH Annual Meeting; December 11, 2021; Atlanta, GA. 62. Saad HKM, Abd Rahman AA, Ab Ghani AS, et al. Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-Thalassemia Patients. Biomedicines. 2022;10(1):189. doi:10.3390/biomedicines10010189. 63. Pilo F, Angelucci E. Vamifeport: Monography of the First Oral Ferroportin Inhibitor. J Clin Med. 2024;13(18):5524. doi:10.3390/jcm13185524. 64. Ganz T. Hepcidin—a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol. 2005;18(2):171-182. doi:10.1016/j.beha.2004.08.020. 65. Cleveland Clinic. Iron-Deficiency Anemia. Revised December, 2024. Accessed August, 2025. Available at: https://my.clevelandclinic.org/health/diseases/22824-iron-deficiency-anemia. 66. Nikitina T, Andreevskaya E, Babich E, et al. P1692: Unmet needs in patients with “low risk” polycythemia vera (PV): symptom burden and quality of life. Poster presented at: The 28th Congress of the European Hematology Association; June 2023; Frankfurt, Germany. 67. Faruqi A, Zubair M, Mukkamalla SKR. Iron-Binding Capacity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 2, 2024.